|Assessment Status||Rapid Review complete|
|Indication||Treatment of vitamin D deficiency (i.e., 25(OH)D levels <25 nmol/L) in adults, for the prevention of vitamin D deficiency in adults with identified risks such as in patients with malabsorption syndrome, chronic kidney disease mineral and bone disorder (CKD-MBD) or other identified risks, and as an adjuvant for the specific treatment of osteoporosis in patients with vitamin D deficiency or at risk of vitamin D deficiency.|
|Rapid review commissioned||12/09/2022|
|Rapid review completed||13/10/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that calcifediol monohydrate (Dnord®) be considered for reimbursement.|
The HSE has approved reimbursement, December 2022.